Vaccine Preventable Diseases and Vaccination Policy for Indigenous Populations

Pediatric Clinics of North America

Volumn 56, Issue 6, 2009, Pages 1263-1283

  Menzies, Robert I ^a   Singleton, Rosalyn J ^b,c  

^a NATIONAL CENTRE FOR IMMUNISATION RESEARCH AND SURVEILLANCE   (Australia)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c ALASKA NATIVE TRIBAL HEALTH CONSORTIUM   (United States)

Author keywords

Health policy; Indigenous population; Vaccination strategy; Vaccine preventable disease

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPATITIS A HEPATITIS B VACCINE; HEPATITIS A VACCINE; INFLUENZA VACCINE; MENINGOCOCCUS VACCINE; OUTER MEMBRANE PROTEIN; PERTUSSIS VACCINE; PNEUMOCOCCUS VACCINE; ROTAVIRUS VACCINE; WART VIRUS VACCINE;

CONDYLOMA ACUMINATUM; DISEASE SURVEILLANCE; DRUG EFFICACY; HAEMOPHILUS INFECTION; HAEMOPHILUS INFLUENZAE TYPE B; HEALTH CARE DELIVERY; HEALTH CARE DISPARITY; HEALTH CARE FINANCING; HEALTH CARE POLICY; HEALTH PROGRAM; HEALTH PROMOTION; HEPATITIS A; HEPATITIS B; HIGH RISK POPULATION; HUMAN; IMMUNE RESPONSE; INDIGENOUS PEOPLE; INFLUENZA; MENINGOCOCCOSIS; MORBIDITY; PERTUSSIS; PNEUMOCOCCAL INFECTION; REVIEW; UTERINE CERVIX CANCER; VACCINATION; VIRUS INFECTION; WART VIRUS;

ADOLESCENT; ADULT; AGED; AUSTRALIA; CANADA; CHILD, PRESCHOOL; COMMUNICABLE DISEASE CONTROL; COMMUNICABLE DISEASES; HEALTH POLICY; HEALTH SERVICES, INDIGENOUS; HEPATITIS A; HEPATITIS B; HUMANS; IMMUNIZATION PROGRAMS; IMMUNIZATION SCHEDULE; INCIDENCE; INFLUENZA, HUMAN; MASS VACCINATION; MIDDLE AGED; NEW ZEALAND; PAPILLOMAVIRUS INFECTIONS; PNEUMOCOCCAL INFECTIONS; POPULATION SURVEILLANCE; ROTAVIRUS INFECTIONS; RURAL HEALTH SERVICES; UNITED STATES; YOUNG ADULT;

EID: 71949110707     PISSN: 00313955     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pcl.2009.09.006     Document Type: Review

References (150)

1. US Census Bureau. The American Indian and Alaska native population. Report num. C2KBR/01-15 (2002), US Census Bureau, Washington, DC
2. Bulkow L.R., Singleton R.J., Karron R.A., et al. Alaska RSV Study Group. Risk factors for severe respiratory syncytial virus infection among Alaska native children. Pediatrics 109 (2002) 210-216
3. Statistics Canada. Canada e-book. Available at:. http://142.206.72.67/r000_e.htm Accessed April 20, 2006
4. Australian Bureau of Statistics (ABS). Australian demographic statistics. Report num. 3101.0 (2003), ABS, Canberra, Australian Capital Territory
5. Statistics New Zealand. Census snapshot: Maori. Available at:. http://www.stats.govt.nz/products-and-services/Articles/census-snpsht-ma ori-Apr02.htm Accessed April 20, 2006
6. Boughton C.R. Smallpox and Australia. Intern Med J 32 (2002) 59-61
7. Newman M.T. Aboriginal new world epidemiology and medical care, and the impact of old world disease imports. Am J Phys Anthropol 45 (1976) 667-672
8. Australian Bureau of Statistics (ABS). Australian Institute of Health and Welfare (AIHW). The health and welfare of Australia's Aboriginal and Torres Strait Islander peoples: 2003. Cat. No. 4704.0. Report num. 4704.0 (2003), ABS, Canberra
9. First Nations and Inuit Health Branch. A statistical profile on the health of First Nations in Canada (2003), Health Canada, Ottawa (ON)
10. New Zealand Ministry of Health. Our health, our future. Hauora pakari, koiora roa. The health of New Zealanders 1999 (1999), New Zealand Ministry of Health, Wellington NZ
11. Palagiano C, Shalala DE, Trujillo MH, et al. Trends in Indian Health, 1998-99 [report]. Indian Health Service, US Department of Health and Human Services, 1999.
12. Ministry of Health. Immunisation handbook 2006 (2006), Ministry of Health, Wellington
13. Hutchins S.S., Jiles R., and Bernier R. Elimination of measles and of disparities in measles childhood vaccination coverage among racial and ethnic minority populations in the United States. J Infect Dis 189 (Suppl 1) (2004) S146-S152
14. National Health and Medical Research Council. The Australian immunisation handbook. 8th edition (2003), Australian Government Department of Health and Ageing, Canberra, Australian Capital Territory
15. National Advisory Committee on Immunization. Canadian immunization guide. 6th edition (2002), Health Canada, Ottawa (ON)
16. Horby P., Gilmour R., Wang H., et al. Progress towards eliminating Hib in Australia: an evaluation of Haemophilus influenzae type b prevention in Australia, 1 July 1993 to 30 June 2000. Commun Dis Intell 27 (2003) 324-341
17. Scheifele D.W., Law B.J., Gold R., et al. Recent trends in pediatric Haemophilus influenzae type b infections in Canada. Can Med Assoc J 154 (1996) 1041-1047
18. Ministry of Health. 2008 National immunisation schedule health provider booklet (2008), Ministry of Health, Wellington
19. Coulehan J.L., Michaelis R.H., Hallowell C., et al. Epidemiology of Haemophilus influenzae type b disease among Navajo Indians. Public Health Rep 99 (1984) 404-409
20. Losonsky G.A., Santosham M., Sehgal V.M., et al. Haemophilus influenzae disease in the white mountain apaches: molecular epidemiology of a high risk population. Pediatr Infect Dis J 3 (1984) 539-547
21. Ward J.I., Margolis H.S., Lum M.K., et al. Haemophilus influenzae disease in Alaskan Eskimos: characteristics of a population with an unusual incidence of invasive disease. Lancet 1 (1981) 1281-1285
22. National Health and Medical Research Council. The Australian immunisation handbook. 9th edition (2008), Australian Government Department of Health and Ageing, Canberra
23. Centers for Disease Control and Prevention (CDC). Recommended childhood and adolescent immunization schedule-United States, 2006. MMWR Morb Mortal Wkly Rep 54 (2006) Q1-Q4
24. Centers for Disease Control and Prevention (CDC). Interim recommendations for the use of Haemophilus influenzae type b (Hib) conjugate vaccines related to the recall of certain lots of Hib-containing vaccines (PedvaxHIB and Comvax). MMWR Morb Mortal Wkly Rep 56 (2007) 1318-1320
25. Hanna J.N. The epidemiology of invasive Haemophilus influenzae infections in children under five years of age in the Northern Territory: a three year study. Med J Aust 152 (1990) 234-240
26. Markey P., Krause V., Boslego J.W., et al. The effectiveness of Haemophilus influenzae type b conjugate vaccines in a high risk population measured using immunization register data. Epidemiol Infect 126 (2001) 31-36
27. Wilson N., Wenger J., Mansoor O., et al. The beneficial impact of Hib vaccine on disease rates in New Zealand children. N Z Med J 115 (2002) U122-U128
28. Menzies R., Turnour C., Chiu C., et al. Vaccine preventable diseases and vaccination coverage in Aboriginal and Torres Strait Islander people, Australia, 2003 to 2006. Commun Dis Intell 32(Suppl) (2008) S2-67
29. Population and Environmental Health Group Institute of Environmental Science and Research Limited. Notifiable and other diseases in New Zealand 2007 [report]. 2009.
30. Population and Environmental Health Group Institute of Environmental Science and Research Limited. Notifiable and other diseases in New Zealand Annual Report 2006 [report]. 2009.
31. Singleton R., Hammit L., Hennessey T., et al. The Alaska Haemophilus influenzae type b experience: lessons in controlling a vaccine-preventable disease. Pediatrics 118 (2006) e421-e429
32. Hanna J. The epidemiology and prevention of Haemophilus influenzae infections in Australian aboriginal children. J Paediatr Child Health 28 (1992) 354-361
33. Hansman D., Hanna J., and Morey F. High prevalence of invasive Haemophilus influenzae disease in central Australia, 1986 (letter). Lancet 2 (1986) 927
34. Galil K., Singleton R., Levine O.S., et al. Reemergence of invasive Haemophilus influenzae type b disease in a well-vaccinated population in remote Alaska. J Infect Dis 179 (1999) 101-106
35. Santosham M., Wolff M., and Reid R. The efficacy in Navajo infants of a conjugate vaccine consisting of Haemophilus influenzae type b polysaccharide and Neisseria meningitidis outer-membrane protein complex. N Engl J Med 324 (1991) 1767-1772
36. Decker M.D., Edwards K.M., Bradley R., et al. Comparative trial in infants of four conjugate Haemophilus influenzae type b vaccines. J Pediatr 120 (1992) 184-189
37. Singleton R., Bulkow L.R., Levine O.S., et al. Experience with the prevention of invasive Haemophilus influenzae type b disease by vaccination in Alaska: the impact of persistent oropharyngeal carriage. J Pediatr 137 (2000) 313-320
38. Millar E.V., O'Brien K.L., Levine O.S., et al. Toward elimination of Haemophilus influenzae type B carriage and disease among high-risk American Indian children. Am J Public Health 90 (2000) 1550-1554
39. Wang H., Deeks S., Glasswell A., et al. Trends in invasive Haemophilus influenzae type b disease in Australia, 1995-2005. Commun Dis Intell 32 (2009) 316-325
40. Scheifele D., Halperin S., Law B., et al. Invasive Haemophilus influenzae type b infections in vaccinated and unvaccinated children in Canada, 2001-2003. CMAJ 172 (2005) 53-56
41. Guthridge S., McIntyre P., Isaacs D., et al. Differing serologic responses to an Haemophilus influenzae type b polysaccharide-Neisseria meningitidis outer membrane protein conjugate (PRP-OMPC) vaccine in Australian Aboriginal and Caucasian infants-implications for disease epidemiology. Vaccine 18 (2000) 2584-2591
42. Centers for Disease Control and Prevention (CDC). Hepatitis A vaccination programs in communities with high rates of hepatitis A. MMWR Morb Mortal Wkly Rep 46 (1997) 600-603
43. Peach D., McMahon B.J., Bulkow L., et al. Impact of recurrent epidemics of hepatitis A virus infection on population immunity levels: Bristol Bay, Alaska. J Infect Dis 186 (2002) 1081-1085
44. Adams L., and Johnson G. Hepatitis A virus infection, immunisation and the Kimberley Public Health Bulletin [letter]. Kimberley P.H. Bull 13 (2003)
45. Hanna J.N., Hills S.L., and Humphreys J.L. Impact of hepatitis A vaccination of Indigenous children on notifications of hepatitis A in north Queensland. Med J Aust 181 (2004) 482-485
46. Bialek S.R., Thoroughman D.A., Hu D., et al. Hepatitis A incidence and hepatitis A vaccination among American Indians and Alaska Natives, 1990-2001. Am J Public Health 94 (2004) 996-1001
47. Advisory Committee on Immunization Practices (ACIP), Fiore A.E., Wasley A., and Bell B.P. Prevention of hepatitis A through active or passive immunization: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 55 RR-7 (2006) 1-23 Centers for Disease Control and Prevention (CDC)
48. National Advisory Committee on Immunization. Canadian immunization guide. 7th edition (2006), Public Health Agency of Canada, Ottawa (ON)
49. Bowden F.J., Currie B.J., Miller N.C., et al. Should aboriginals in the "top end" of the Northern Territory be vaccinated against hepatitis A?. Med J Aust 161 (1994) 372-373
50. Hanna J.N., Hills S.L., and Humphreys J.L. The impact of hepatitis A vaccination of Indigenous children on the incidence of hepatitis A in North Queensland. Med J Aust 181 9 (2004) 482-485
51. Bulkow L.R., Wainwright R.B., McMahon B.J., et al. Secular trends in hepatitis A virus infection among Alaska Natives. J Infect Dis 168 (1993) 1017-1020
52. Welty T.K., Darling K., Dye S., et al. Guidelines for prevention and control of hepatitis A in American Indian and Alaska Native communities. [erratum appears in S D J Med 1997 May;50(5):179]. S D J Med 49 (1996) 317-322
53. Centers for Disease Control and Prevention (CDC). Prevention of hepatitis A through active or passive immunization: Recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep 45 RR-15 (1996) 15-20
54. Australian Government Department of Health and Ageing. Indigenous immunisation program. Available at:. http://www.immunise.health.gov.au/internet/immunise/publishing.nsf/Conte nt/atsi2 Accessed January 24, 2006
55. Sante et services sociaux. Regular vaccination schedule. Available at:. http://www.msss.gouv.qc.ca/sujets/santepub/vaccination/index.php?calendr ier_de_vaccination_en Accessed June 12, 2009
56. Centers for Disease Control and Prevention (CDC). Surveillance for acute viral hepatitis, 2007. MMWR Surveill Summ 58 SS-3 (2009) 1-27
57. Centers for Disease Control and Prevention (CDC). Protection against viral hepatitis: recommendations of the Immunization Practices Advisory Committee. MMWR Recomm Rep 39 RR-2 (1990) 2-3
58. McMahon B.J., Schoenberg S., Bulkow L., et al. Seroprevalence of hepatitis B viral markers in 52,000 Alaska Natives. Am J Epidemiol 138 (1993) 544-549
59. Schreeder M.T., Bender T.R., McMahon B.J., et al. Prevalence of hepatitis B in selected Alaskan Eskimo villages. Am J Epidemiol 118 (1983) 543-549
60. Kaldor J.M., Plant A.J., Thompson S.C., et al. The incidence of hepatitis B infection in Australia: an epidemiologic review. Med J Aust 165 (1996) 322-326
61. Minuk G.Y., and Uhanova J. Viral hepatitis in the Canadian Inuit and First Nations populations. Can J Gastroenterol 17 (2003) 707-712
62. Blakely T., Salmond C., and Tobias M. Hepatitis B virus carrier prevalence in New Zealand: population estimates using the 1987 police and customs personnel survey. N Z Med J 111 (1998) 142-144
63. Centers for Disease Control and Prevention (CDC). Acute hepatitis B among children and adolescents-United States, 1990-2002. MMWR Morb Mortal Wkly Rep 53 (2004) 1015-1018
64. Canadian Nursing Coalition on Immunization. Provincial and territorial immunization programs. Available at:. http://www.phac-aspc.gc.ca/im/ptimprog-progimpt/table-1_e.html Accessed April 20, 2006
65. Wan X., and Mathews J.D. Primary hepatocellular carcinoma in Aboriginal Australians. Aust N Z J Public Health 18 (1994) 286-290
66. Patrick D.M., Bigham M., Ng H., et al. Elimination of acute hepatitis B among adolescents after one decade of an immunization program targeting Grade 6 students. Pediatr Infect Dis J 22 (2003) 874-877
67. Minuk G.Y., Zhang M., Wong S.G., et al. Viral hepatitis in a Canadian First Nations community. Can J Gastroenterol 17 (2003) 593-596
68. McMahon B.J., Rhoades E.R., Heyward W.L., et al. A comprehensive programme to reduce the incidence of hepatitis B virus infection and its sequelae in Alaskan natives. Lancet 2 (1987) 1134-1136
69. Heyward W.L., Bender T.R., McMahon B.J., et al. The control of hepatitis B virus infection with vaccine in Yupik Eskimos. Demonstration of safety, immunogenicity, and efficacy under field conditions. Am J Epidemiol 121 (1985) 914-923
70. National Health and Medical Research Council. The Australian immunisation procedures handbook. 5th edition (1994), Australian Government Publishing Service, Canberra, Australian Capital Territory
71. New Zealand Ministry of Health. Immunisation handbook (2002), New Zealand Ministry of Health, Wellington, New Zealand
72. Carlson J., Stratton F., Delage G., et al. Report of the hepatitis B working group. Can Commun Dis Rep 20 (1994) 105-112
73. Centers for Disease Control and Prevention (CDC). Hepatitis B virus: a comprehensive strategy for eliminating transmission in the US through universal childhood vaccination: Recommendations of the Immunization Advisory Committee. MMWR Recomm Rep 40 RR-13 (1991) 1-25
74. Harpaz R., McMahon B.J., Margolis H.S., et al. Elimination of new chronic hepatitis B virus infections: results of the Alaska immunization program. J Infect Dis 181 (2000) 413-418
75. Oman K.M., Carnie J., and Ruff T.A. Hepatitis B immunisation rates among infants in ethnic groups with high prevalences of hepatitis B surface antigen carriers. Aust N Z J Public Health 21 (1997) 293-296
76. Alter M.J., Hadler S.C., Margolis H.S., et al. The changing epidemiology of hepatitis B in the United States. JAMA 263 (1990) 1218-1222
77. Centers for Disease Control and Prevention (CDC). Surveillance for acute viral hepatitis-United States, 2006. MMWR Surveill Summ 57 SS-2 (2008) 1-24
78. Centers for Disease Control and Prevention (CDC). Recommended immunization schedules for persons aged 0 through 18 years-United States, 2009. MMWR Morb Mortal Wkly Rep 57 (2009) Q1-Q4
79. O'Brien E.D., Bailie R.S., and Jelfs P.L. Cervical cancer mortality in Australia: contrasting risk by Aboriginality, age and rurality. Int J Epidemiol 29 (2009) 813-816
80. Dachs G.U., Currie M.J., McKenzie F., et al. Cancer disparities in indigenous Polynesian populations: Maori, Native Hawaiians, and Pacific people. Lancet 9 (2009) 473-484
81. Leman R.F., Espey D.K., and Cobb N. Invasive cervical cancer among American Indian women in the Northern Plains, 1994-1998. Public Health Rep 120 (2005) 283-287
82. Ehrsam G., Lanier A., and Sandidge J. Cancer mortality among Alaska Natives, 1994-1998. Ala Med 43 (2001) 50-60
83. Bowden F.J., Tabrizi S.N., Paterson B.A., et al. Determination of genital human papillomavirus genotypes in women in Northern Australia using a novel, self-administered tampon technique. Int J Gynecol Cancer 8 (2009) 471-475
84. Becker T.M., Espey D.K., Lawson H.W., et al. Regional differences in cervical cancer incidence among American Indians and Alaska Natives, 1999-2004. Cancer 113 (2008) 1234-1243
85. D'Onise K., and Raupach C.A.J. The burden of influenza in healthy children in South Australia. Med J Aust 188 (2009) 510-513
86. Groom A.V., Jim C., Laroque M., et al. Pandemic influenza preparedness and vulnerable populations in tribal communities. Am J Publ Health 99 Suppl 2 (2009) S271-S278 [Epub 2009 May 21]
87. Centers for Disease Control and Prevention (CDC)Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep 53 RR-6 (2004) 1-40
88. Centers for Disease Control and Prevention (CDC). Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2008. MMWR Morb Mortal Wkly Rep 57 RR-7 (2008) 1-60
89. National Advisory Committee on Immunization (NACI). Statement on influenza vaccination for the 2008-2009 season. An Advisory Committee Statement (ACS). Can Commun Dis Rep 34 ACS-3 (2008) 1-46
90. Lacapa R., Bliss S.J., Larzelere-Hinton F., et al. Changing epidemiology of invasive pneumococcal disease among White Mountain Apache persons in the era of the pneumococcal conjugate vaccine. Clin Infect Dis 47 (2008) 476-484
91. Rudolph K.M., Parkinson A.J., Reasonover A.L., et al. Serotype distribution and antimicrobial resistance patterns of invasive isolates of Streptococcus pneumoniae: Alaska, 1991-1998. J Infect Dis 182 (2000) 490-496
92. Torzillo P.J., Hanna J., Morey F., et al. Invasive pneumococcal disease in central Australia. Med J Aust 162 (1995) 182-186
93. Hanna J.N., McCall B., and Murphy D. Invasive meningococcal disease in north Queensland, 1990-1994. Commun Dis Intell 20 (1996) 320-324
94. Krause V.L., Reid S.J., and Merianos A. Invasive pneumococcal disease in the Northern Territory of Australia, 1994-1998. Med J Aust 173 Suppl (2000) S27-S31
95. Giele C., Moore H., Bayley K., et al. Has the seven-valent pneumococcal conjugate vaccine had an impact on invasive pneumococcal disease in Western Australia?. Vaccine 25 (2009) 2379-2384
96. Bruce M, Cottle T, Parkinson A. International Circumpolar Surveillance (ICS) summary report. Arctic investigations program, Centers for Disease Control, 2005.
97. Nicolaeva MA, Huntly P, Dumaresq G. Immunization coverage and incidence rates in Canadian First Nations children on-reserve. 2009. (GENERIC) Ref Type: Conference Proceeding.
98. Voss L., Lennon D., Okesene-Gafa K., et al. Invasive pneumococcal disease in a pediatric population, Auckland, New Zealand. Pediatr Infect Dis J 13 (1994) 873-878
99. Cortese M.M., Wolff M., Almeido-Hill J., et al. High incidence rates of invasive pneumococcal disease in the White Mountain Apache population. Arch Intern Med 152 (1992) 2277-2282
100. Davidson M., Parkinson A.J., Bulkow L.R., et al. The epidemiology of invasive pneumococcal disease in Alaska, 1986 to 1990-ethnic differences and opportunities for prevention. J Infect Dis 170 (1994) 368-376
101. O'Brien K.L., Shaw J., Weatherholtz R., et al. Epidemiology of invasive Streptococcus pneumoniae among Navajo children in the era before use of conjugate pneumococcal vaccines, 1989-1996. Am J Epidemiol 160 (2004) 270-278
102. Roche P., Krause V., and Cook H. Invasive pneumococcal disease in Australia, 2006. Commun Dis Intell 32 (2008) 18-30
103. Centers for Disease Control and Prevention (CDC). Summary of notifiable diseases-United States, 2003 [report]. MMWR Surveill Summ 52 54 (2005) 1-85
104. Hennessy T.W., Singleton R.J., Bulkow L.R., et al. Impact of heptavalent pneumococcal conjugate vaccine on invasive disease, antimicrobial resistance and colonization in Alaska natives: progress towards elimination of a health disparity. Vaccine 23 (2005) 5464-5473
105. Zangwill K.M., Vadheim C.M., Vannier A.M., et al. Epidemiology of invasive pneumococcal disease in southern California: implications for the design and conduct of a pneumococcal conjugate vaccine efficacy trial. J Infect Dis 174 (1996) 752-759
106. In: Plotkin S.A., and Orenstein W.A. (Eds). Vaccines. 4th edition (2004), WB Saunders, Philadelphia
107. Lucero M.G., Dulalia V.E., Parreno R.N., et al. Pneumococcal conjugate vaccines for preventing vaccine-type invasive pneumococcal disease and pneumonia with consolidation on X-ray in children under two years of age. Review. Cochrane Database Syst Rev 4 (2004) CD004977
108. Straetemans M., Sanders E.A.M., Veenhoven R.H., et al. Pneumococcal vaccines for preventing otitis media. Review. Cochrane Database Syst Rev 1 (2005) CD001480
109. McIntyre P.B., and Nolan T.M. Conjugate pneumococcal vaccines for non-Indigenous children in Australia. Med J Aust 173 (2000) S54-S57
110. Scheifele D., Law B., Vaudry W., et al. Invasive pneumococcal infections among Canadian aboriginal children. Can Commun Dis Rep 29 (2003) 37-42
111. Singleton R.J., Hennessey T., Bulkow L., et al. Invasive pneumococcal disease caused by nonvaccine serotypes among Alaska Native children with high levels of 7-valent pneumococcal conjugate vaccine coverage. JAMA 297 (2007) 1784-1792
112. Hanna J.N., Humphreys J.L., and Murphy D.M. Invasive pneumococcal disease in Indigenous people in north Queensland: an update, 2005-2007. Med J Aust 189 (2009) 43-46
113. Morris P.S. A systematic review of clinical research addressing the prevalence, aetiology, diagnosis, prognosis and therapy of otitis media in Australian Aboriginal children. J Paediatr Child Health 34 (1998) 487-497
114. Grijalva C.G., Poehling K.A., Nuorti J.P., et al. National impact of universal childhood immunization with pneumococcal conjugate vaccine on outpatient medical care visits in the United States. Pediatrics 118 (2006) 865-873
115. Jardine A., Menzies R., Deeks S., et al. The impact of pneumococcal conjugate vaccine on rates of myringotomy with ventilation tube insertion in Australia. Pediatr Infect Dis J 28 9 (2009) 761-765
116. Singleton R.J., Holman R.C., Plant R., et al. Trends in otitis media and myringtomy with tube placement among American Indian/Alaska native children and the US general population of children. Pediatr Infect Dis J 28 (2009) 102-107
117. Leach A.J., and Morris P.S. The burden and outcome of respiratory tract infection in Australian and Aboriginal children. Pediatr Infect Dis J 26 (2009) S4-S7
118. Health Canada. First nations health status report, Alberta region, 2007-2008 (2009), Health Canada, Ottawa (ON)
119. Glass R.I., Lew J.F., Gangarosa R.E., et al. Estimates of morbidity and mortality rates for diarrheal diseases in American children. J Pediatr 118 4[Pt 2] (1991) S27-S33
120. Holman R.C., Parashar U.D., Clarke M.J., et al. Trends in diarrhea-associated hospitalizations among American Indian and Alaska native children, 1980-1995. Pediatrics 103 (1999) E11
121. Singleton R.J., Holman R.C., Yorita K.L., et al. Diarrhea-associated hospitalizations and outpatient visits among American Indian and Alaska Native children younger than five years of age, 2000-2004. Pediatr Infect Dis J 26 (2007) 1006-1013
122. Vesikari T., Matson D.O., Dennehy P., et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 354 (2006) 23-33
123. Northern Territory Government. Territory to fund rotavirus vaccine. Available at:. http://newsroom.nt.gov.au/index.cfm?fuseaction=printRelease&ID=287 Accessed June 12, 2009
124. Commonwealth Department of Health and Ageing. Fact sheets: Australian government funding of rotavirus vaccine. Available at:. http://www.health.gov.au/internet/main/publishing.nsf/Content/rotavirus_ vaccine.htm Accessed June 12, 2009
125. National Advisory Committee on Immunization (NACI). Statement on the recommended use of pentavalent human-bovine reassortant rotavirus vaccine. An Advisory Committee Statement (ACS). Can Commun Dis Rep 34 ACS-1 (2008) 1-33
126. Centers for Disease Control and Prevention (CDC). Delayed onset and diminished magnitude of rotavirus activity-United States, November 2007-May 2008. MMWR Morb Mortal Wkly Rep 57 (2008) 697-700
127. Centers for Disease Control and Prevention (CDC). Recommended childhood and adolescent immunization schedule-United States, January-June 2004. MMWR Morb Mortal Wkly Rep 53 (2004) Q1-Q4
128. New Zealand Ministry of Health. Immunisation schedule. Available at:. http://www.moh.govt.nz/mohnsf/indexmh/immunisation-schedule Accessed April 20, 2006
129. Public Health Agency of Canada. Immunization schedule. Available at:. http://www.phac-aspc.gc.ca/im/is-cv/index.html Accessed April 20, 2006
130. Miller M., Roche P., Yphannes K., et al. Australia's notifiable disease status, 2003: annual report of the National Notifiable Diseases Surveillance System. Commun Dis Intell 29 (2005) 1-61
131. Vitek C.R., Pascual F.B., Baughman A.L., et al. Increase in deaths from pertussis among young infants in the United States in the 1990s. Pediatr Infect Dis J 22 (2003) 628-634
132. Menzies R., McIntyre P., and Beard F. Vaccine preventable diseases and vaccination coverage in Aboriginal and Torres Strait Islander people, Australia, 1999 to 2002. Commun Dis Intell 28 Suppl 1 (2004) S1-S45
133. Centers for Disease Control and Prevention (CDC) Prevention and control of meningococcal disease. [report]. MMWR Recomm Rep 54 (2005) RR07, 1-21
134. O'Hallahan J., Lennon D., and Oster P. The strategy to control New Zealand's epidemic of group B meningococcal disease. Pediatr Infect Dis J 23 (2004) S293-S298
135. Martin D, Lopez L. The epidemiology of meningococcal disease in New Zealand in 2007. Report num. FW 0841. Environmental Science and Research Ltd, 2008.
136. Centers for Disease Control and Prevention (CDC). Estimated vaccination coverage with individual vaccines and vaccination series among children 19-35 months of age by race/ethnicity. US, National Immunization Survey, Q1/2007-Q4/2007. Available at:. http://www.cdc.gov/vaccines/stats-surv/nis/tables/07/tab30_race_nat.xls Accessed June 12, 2009
137. Hull B.P., and McIntyre P.B. Timeliness of childhood vaccination in Australia. Vaccine 24 (2006) 4403-4408
138. Vlack S.A., Foster R., Menzies R., et al. Immunisation coverage of Queensland Indigenous 2 year old children by cluster sampling and by register. Aust N Z J Public Health 31 (2007) 67-72
139. Ministry of Health. The National childhood immunisation coverage survey 2005 (2009), Ministry of Health, Wellington
140. National American Indian Housing Council (NAIHC). Too few rooms: residential crowding in Native American communities and Alaska Native villages [report] (2001), NAIHC, Washington, DC
141. Hennessy T.W., Ritter T., Holman R.C., et al. The relationship between in-home water service and the risk of respiratory tract, skin, and gastrointestinal tract infections among rural Alaska natives. Am J Public Health 98 (2008) 2072-2078
142. Australian Bureau of Statistics (ABS), Australian Institute of Health and Welfare (AIHW). The health and welfare of Australia's Aboriginal and Torres Strait Islander peoples, 2005. Cat. No. 4704.0. Report num. Report Num 4704.0 (2005), ABS, Canberra
143. Hanna J.N., Faoagali J.L., Buda P.J., et al. Further observations on the immune response to recombinant hepatitis B vaccine after administration to aboriginal and Torres Strait Island children. J Paediatr Child Health 33 (1997) 67-70
144. Siber G., Santosham M., and Reid R. Impaired antibody response to Haemophilus influenzae type b polysaccharide and low IgG2 and IgG4 concentrations in Apache children. N Engl J Med 323 (1990) 1387-1392
145. Miernyk K.M., Parkinson A.J., Rudolph K.M., et al. Immunogenicity of a heptavalent pneumococcal conjugate vaccine in Apache and Navajo Indian, Alaska native, and non-native American children aged <2 years. Clin Infect Dis 31 (2000) 34-41
146. O'Brien K.L., Moulton L.H., Reid R., et al. Efficacy and safety of seven-valent conjugate pneumococcal vaccine in American Indian children: group randomised trial. Lancet 362 (2003) 355-361
147. Watt J.P., O'Brien K.L., Benin A.L., et al. Invasive pneumococcal disease among Navajo adults, 1989-1998. Clin Infect Dis 38 (2004) 496-501
148. Bulkow L., Wainwright R., Letson G.W., et al. Comparative immunogenicity of 4 Haemophilus influenzae type b conjugate vaccines in Alaskan Native infants. Pediatr Infect Dis J 12 (1993) 484-492
149. Squires S.G., and Pelletier L. Publicly-funded influenza and pneumococcal immunization programs in Canada: a progress report. Can Commun Dis Rep 26 (2000) 141-148
150. Hanna J.N., Young D.M., Brookes D.L., et al. The initial coverage and impact of the pneumococcal and influenza vaccination program for at-risk indigenous adults in Far North Queensland. Aust N Z J Public Health 25 (2001) 543-546